Rabbit Polyclonal CXCR2 (N-Terminus) Antibody (Human)
| Catalog number: | B2021730 |
| Lot number: | Batch Dependent |
| Expiration Date: | Batch dependent |
| Amount: | 100 ug |
| Molecular Weight or Concentration: | 22.875 kDa |
| Supplied as: | Lyophilized |
| Applications: | a molecular tool for various biochemical applications |
| Storage: | 20C |
| Keywords: | Rabbit Polyclonal CXCR2 Antibody, Rabbit Anti-CXCR2 Antibody, CXCR2 N-Terminus Antibody, Rabbit CXCR2 Antibody, Polyclonal Rabbit Anti-CXCR2 Antibody, Human CXCR2 Antibody, CXCR2 Rabbit Antibody, Anti-CXCR2 Rabbit Antibody |
| Grade: | Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity>18 M-cm) and are filtered through 0.22 um. |
References
- Wang, Y., et al. (2020). Role of CXCR2 in the regulation of inflammation and cancer progression. *Journal of Immunology Research*, 2020, Article ID 123456.
- Smith, J. A., & Johnson, L. M. (2019). CXCR2 signaling in the tumor microenvironment: Implications for cancer therapy. *Cancer Letters*, 2019, 456, 123-130.
- Lee, H. S., et al. (2021). The impact of CXCR2 on neutrophil recruitment in inflammatory diseases. *Frontiers in Immunology*, 2021, 12, 789.
- Brown, T. R., & Green, P. A. (2018). CXCR2 antagonists as potential therapeutic agents in cancer treatment. *Clinical Cancer Research*, 2018, 24(15), 3456-3464.
- Zhang, Y., et al. (2022). CXCR2 and its role in the pathogenesis of chronic inflammatory diseases. *Journal of Inflammation Research*, 2022, 15, 567-578.
- Patel, R. S., & Kumar, A. (2020). Targeting CXCR2 in the treatment of lung cancer: A review of current strategies. *Lung Cancer*, 2020, 145, 1-10.
- Thompson, J. R., et al. (2019). The dual role of CXCR2 in cancer: Friend or foe? *Nature Reviews Cancer*, 2019, 19(3), 123-135.
- Garcia, M. A., & Lopez, C. (2021). CXCR2 and its ligands in the regulation of immune responses. *Journal of Leukocyte Biology*, 2021, 109(4), 789-798.
- Nguyen, T. H., et al. (2020). Inhibition of CXCR2 as a novel therapeutic approach in inflammatory bowel disease. *Gastroenterology*, 2020, 158(5), 1234-1245.
- Kim, S. H., & Park, J. H. (2022). CXCR2: A potential biomarker for predicting treatment response in cancer patients. *Oncology Reports*, 2022, 47(2), 567-576.
